| 000 | 01516 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250513035352.0 | ||
| 264 | 0 | _c19950929 | |
| 008 | 199509s 0 0 eng d | ||
| 022 | _a1060-0280 | ||
| 024 | 7 |
_a10.1177/106002809502900501 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOster, G | |
| 245 | 0 | 0 |
_aEffects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis. _h[electronic resource] |
| 260 |
_bThe Annals of pharmacotherapy _cMay 1995 |
||
| 300 |
_a459-64 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCystic Fibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aDeoxyribonuclease I _xtherapeutic use |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aExpectorants _xtherapeutic use |
| 650 | 0 | 4 |
_aHealth Services _xeconomics |
| 650 | 0 | 4 |
_aHospitalization _xeconomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
| 650 | 0 | 4 |
_aRespiratory Tract Infections _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aHuse, D M | |
| 700 | 1 | _aLacey, M J | |
| 700 | 1 | _aRegan, M M | |
| 700 | 1 | _aFuchs, H J | |
| 773 | 0 |
_tThe Annals of pharmacotherapy _gvol. 29 _gno. 5 _gp. 459-64 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/106002809502900501 _zAvailable from publisher's website |
| 999 |
_c7654558 _d7654558 |
||